Development of approaches for evaluating the pharmacokinetics of meropenem during endolymphatic antibiotic treatment in critically ill patients

封面

如何引用文章

全文:

详细

Introduction: The use of conventional methods of drug administration during antibiotic therapy of critically ill patients may be insufficient since the minimum inhibitory concentration required for effective therapy may not be maintained for the required amount of time due to the peculiarities of the patients’ pharmacokinetics. Endolymphatic therapy has been proposed as an alternative approach.
Aim: The evaluation of meropenem pharmacokinetics during endolymphatic antibiotic therapy and its comparison to intravenous administration route.
Materials and methods: The blood samples from patients treated with meropenem endolymphatically (n = 1) and intravenously (n = 1) were analyzed using high-performance liquid chromatography with diode-array detection and high-performance liquid chromatography with electrospray ionization tandem mass-spectrometry.
Results: In intravenous and endolymphatic administration of meropenem minimum plasma concentration at steady state was 10 μg/ml and16.39 μg/ml, maximum plasma concentration at steady state – 42.41 μg/ml and 42.57 μg/ml, area under the curve at steady state – 363.997 μg·h·ml-1 and 521.86 μg·h·ml-1, mean residence time – 8.446 and 11.365 hours.
Conclusion: Our results demonstrate longer persistence of meropenem in circulation after endolymphatic administration thus indicating preferable pharmacokinetics. Additionally, minimum plasma concentration at steady state after endolymphatic treatment remained at a high level, exceeding minimum inhibitory concentration. However, further studies in larger cohorts are required for obtaining reliable confirmations of endolymphatic administration route benefits.

参考

  1. Drusano G. Meropenem: laboratory and clinical data. Clin Microbiol Infect. 1997;3 Suppl 4:S51-S59.
  2. https://doi.org/10.1016/S1198-743X(14)65034-5
  3. Salmon-Rousseau A, Martins C, Blot M, et al. Comparative review of imipenem/ cilastatin versus meropenem. Med Mal Infect. 2020;50(4):316-322.
  4. https://doi.org/10.1016/j.medmal.2020.01.001
  5. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet. 2000;39(3):185-201.
  6. https://doi.org/10.2165/00003088-200039030-00002
  7. Steffens NA, Zimmermann ES, Nichelle SM, Brucker N. Meropenem use and therapeutic drug monitoring in clinical practice: a literature review. J Clin Pharm Ther. 2021;46(3):610-621.
  8. https://doi.org/10.1111/jcpt.13369
  9. Alsultan A, Dasuqi SA, Aljamaan F, et al. Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia. Saudi Pharm J. 2021;29(11):1272-1277.
  10. https://doi.org/10.1016/j.jsps.2021.09.017
  11. Vtorenko VI, Esipov AV, Musailov VA, Shishlo VK. Lymphatic therapy in surgical practice. Surgical practice (Russia). 2014; 2014(3):29-34. (In Russian).
  12. Petrenko NA, Groshilin VS, Davidenko AV, Lukash YV. Clinical efficiency of a comprehensive multifactorial approach to the treatment of forearm phlegmon. Ulyanovsk Medical and Biological Journal. 2017;2017(2):104-110. (In Russian). https://doi.org/10.23648/UMBJ.2017.26.6224
  13. Vyrenkov YE, Kataev SI, Kharitonov VV, et al. Endolymphatic administration of drugs in the treatment of purulent-inflammatory diseases. Bulletin of the Ivanovo Medical Academy. 2015;20(4):57-63. (In Russian).
  14. Syomkin VA, Nadtochiy AG, Vozgoment OV, Ivanova AA. Lymphatic therapy and its importance in the complex treatment of patients. Stomatologiia (Mosk). 2020;99(5):116-121. (In Russian).
  15. https://doi.org/10.17116/stomat202099051116
  16. Roberts JA, Croom K, Adomakoh N. Continuous infusion of beta-lactam antibiotics: narrative review of systematic reviews, and implications for outpatient parenteral antibiotic therapy. Expert Rev Anti Infect Ther. 2023;21(4):375-385. https://doi.org/10.1080/14787210.2023.2184347
  17. Razzazzadeh S, Darazam IA, Hajiesmaeili M, et al. Investigation of pharmacokinetic and clinical outcomes of various meropenem regimens in patients with ventilatorassociated pneumonia and augmented renal clearance. Eur J Clin Pharmacol. 2022;78(5):823-829. https://doi.org/10.1007/s00228-022-03291-5
  18. Murray F, Yoo O, Brophy-Williams S, et al. Safety, tolerability and pharmacokinetics of subcutaneous meropenem as an alternative to intravenous administration. J Antimicrob Chemother. 2025;80(1):209-215.
  19. https://doi.org/10.1093/jac/dkae398
  20. Wang Y, Li Z, Chen W, et al. Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study. J Clin Pharm Ther. 2021;46(3):754-761.
  21. https://doi.org/10.1111/jcpt.13344
  22. Gan Y, Meng X, Lei N, Yu H, Zeng Q, Huang Q. Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients. Infect Drug Resist. 2023;16:3989- 3997.
  23. https://doi.org/10.2147/IDR.S408572
  24. Corcione S, D’Avolio A, Loia RC, et al. Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment? J Glob Antimicrob Resist. 2020;20:22-27. https://doi.org/10.1016/j.jgar.2019.06.011
  25. Corona A, De Santis V, Agarossi A, et al. Antibiotic Therapy Strategies for Treating Gram-Negative Severe Infections in the Critically Ill: A Narrative Review. Antibiotics (Basel). 2023;12(8):1262. Published 2023 Jul 31.
  26. https://doi.org/10.3390/antibiotics12081262.
  27. Raza A, Ngieng SC, Sime FB, et al. Oral meropenem for superbugs: challenges and opportunities. Drug Discov Today. 2021;26(2):551-560.
  28. https://doi.org/10.1016/j.drudis.2020.11.004
  29. Selig DJ, Akers KS, Chung KK, Pruskowski KA, Livezey JR, Por ED. Meropenem pharmacokinetics in critically ill patients with or without burn treated with or without continuous veno-venous haemofiltration. Br J Clin Pharmacol. 2022;88(5):2156-2168. https://doi.org/10.1111/bcp.15138
  30. Wise R, Logan M, Cooper M, Ashby JP, Andrews JM. Meropenem pharmacokinetics and penetration into an inflammatory exudate. Antimicrob Agents Chemother. 1990;34(8):1515-1517. https://doi.org/10.1128/AAC.34.8.1515
  31. Olivença F, Pires D, Silveiro C, et al. Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2024;68(4):e0158623.
  32. https://doi.org/10.1128/aac.01586-23

补充文件

附件文件
动作
1. JATS XML
下载